Clinical evaluation of three types of plasmapheresis in a patient with type IIa familial hypercholesterolemia
β Scribed by Akio Mimori; Koki Takahashi; Tadayuki Mitamura; Hirokazu Kato; Tamio Teramoto; Issei Komuro; Zenichiro Honda; Shigeto Toma; Terumasa Miyamoto
- Publisher
- John Wiley and Sons
- Year
- 1987
- Tongue
- English
- Weight
- 498 KB
- Volume
- 3
- Category
- Article
- ISSN
- 0733-2459
No coin nor oath required. For personal study only.
β¦ Synopsis
Long-term plasmaphercsis (PP) therapy was studied in a 56-year-old patient with homozygous type IIa familial hypercholestcrolemia also suffering from severe coronary heart disease. Three different PP techniques, plasma exchange (PE), double-membrane-filtration plasmapheresis (DFP), and the recently developed low-density lipoprotein adsorbent column (adsorption plasmapheresis, adsorption PP), were used in an attempt to develop better means of managing the discase. All three techniques showed similar elimination efficiency with respect to plasma total cholesterol level. Adsorption PP with minimal supplemental plasma protein managed the circulatory status of the patient better than DFP during extracorporeal treatment. In the course of PP therapy xanthoma tuberosum markedly regressed, and the cardiac status of the patient was clearly improved.
π SIMILAR VOLUMES
Chromosomal analyses were performed on lymphocytes, fibroblasts and lymphoblastoid cell lines derived from a Saudi family with ataxia telangiectasia (AT). The three siblings of a consanguineous marriage were all affected. The lymphocytes of the AT homozygotes (probands) showed an increase of 2- to 6
We report on the clinical, pathological, and genetic features of 7 patients with limb-girdle muscular dystrophy type 2A (LGMD2A) from three Japanese families. The mean age of onset was 9.7 Β± 3.1 years (mean Β± SD), and loss of ambulance occurred at 38.5 Β± 2.1 years. Muscle atrophy was predominant in
N-terminal procollagen-III peptide (P-III-P) has been considered a marker of fibrogenesis and inflammatory activity of the liver. We measured the P-III-P serum levels in 83 cirrhotic patients fully characterized from a clinical and laboratory point of view. Cirrhotic patients had significantly highe